- Home
- AUTL vs PDT Comparison
AUTL vs PDT Comparison
Compare AUTL & PDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- PDT
- Stock Information
- Founded
- AUTL 2014
- PDT 1989
- Country
- AUTL United Kingdom
- PDT United States
- Employees
- AUTL N/A
- PDT N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- PDT Finance Companies
- Sector
- AUTL Health Care
- PDT Finance
- Exchange
- AUTL Nasdaq
- PDT Nasdaq
- Market Cap
- AUTL 609.4M
- PDT 648.3M
- IPO Year
- AUTL 2018
- PDT N/A
- Fundamental
- Price
- AUTL $2.29
- PDT $12.25
- Analyst Decision
- AUTL Strong Buy
- PDT
- Analyst Count
- AUTL 3
- PDT 0
- Target Price
- AUTL $10.20
- PDT N/A
- AVG Volume (30 Days)
- AUTL 1.8M
- PDT 145.6K
- Earning Date
- AUTL 11-12-2024
- PDT 01-01-0001
- Dividend Yield
- AUTL N/A
- PDT 8.88%
- EPS Growth
- AUTL N/A
- PDT N/A
- EPS
- AUTL N/A
- PDT N/A
- Revenue
- AUTL $10,091,000.00
- PDT N/A
- Revenue This Year
- AUTL $940.05
- PDT N/A
- Revenue Next Year
- AUTL $238.49
- PDT N/A
- P/E Ratio
- AUTL N/A
- PDT N/A
- Revenue Growth
- AUTL 82.71
- PDT N/A
- 52 Week Low
- AUTL $2.20
- PDT $8.77
- 52 Week High
- AUTL $7.45
- PDT $13.05
- Technical
- Relative Strength Index (RSI)
- AUTL 28.90
- PDT 34.26
- Support Level
- AUTL $2.44
- PDT $11.96
- Resistance Level
- AUTL $2.97
- PDT $13.08
- Average True Range (ATR)
- AUTL 0.18
- PDT 0.20
- MACD
- AUTL -0.04
- PDT -0.09
- Stochastic Oscillator
- AUTL 8.82
- PDT 23.77
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund II is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest growth of capital. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, and short-term investments.